Sinjard 10 mg Tablet contains Empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor. It is primarily used to manage Type 2 Diabetes Mellitus by promoting the excretion of glucose through urine, thereby lowering blood sugar levels. Additionally, Empagliflozin has been shown to reduce the risk of cardiovascular death in patients with Type 2 diabetes and established cardiovascular disease